Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Hyperfine, Inc. filings on SEC EDGAR ↗
Hyperfine, Inc. reported total sales of $13.77 million for the nine months ended September 30, 2026, a significant increase from $8.27 million in the prior year period. Despite the revenue growth, the company recorded a net loss of $23.90 million for the period, though this was an improvement over the $29.66 million net loss reported in the same period of 2025.
Hyperfine reported record third-quarter 2026 revenue of $6.0 million, a 73% increase year-over-year, driven by the sale of 14 Swoop portable MRI systems. The company achieved its narrowest quarterly operating loss of $7.3 million and record gross margins of 57%. Management highlighted that quarterly revenue exceeded net cash burn for the first time, demonstrating significant operating leverage.
Term
Q3 2026
“Q3 2026 marked the beginning of a new trajectory for Hyperfine. We delivered record revenue, gross profit, and gross margin, and for the first time quarterly revenue exceeded net cash burn, demonstrating the operating leverage of our business.”
Maria Sainz, President and Chief Executive Officer of Hyperfine, Inc.
“Beyond our current business, I am excited about the opportunities for our Swoop® system in the evolving brain health and longevity fields. This is the new Hyperfine.”
Maria Sainz, President and Chief Executive Officer of Hyperfine, Inc.
Hyperfine reported preliminary unaudited third quarter 2026 revenue of approximately $6.0 million, representing 53% sequential growth. The company also reported estimated cash and cash equivalents of $37.9 million and reaffirmed its full-year 2026 revenue guidance of $20 million to $22 million.
Hyperfine, Inc. received a deficiency notice from Nasdaq on September 17, 2026, because its Class A common stock closing bid price fell below the $1.00 minimum requirement for 30 consecutive business days. The company has until March 16, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. If compliance is not met, the company may be eligible for an additional 180-day period if it transfers to The Nasdaq Capital Market and meets other listing standards.